Since its 2017 inception, We granted over $7 million federal funding from the National Institutes of Health and the National Science Foundation. IVDS provides contract development and consulting services to partner companies.
WE DELIVER RESULTS
More than 25 years experience in product development and solid phase chemistry.
Extensive expertise in analytical methods, process development, and formulation chemistry.
Instrumental in over 10 commercial products, key licensing agreements, 5 U.S. Patents, and co-author of 12 SBIR grants.
Expertise lies in formulation chemistry, blood separation, and the semi- and quantitative determination of analytes in biological fluids.
Development and commercialization of Point-of-Care Diagnostic Tests.
“I have known Rob for 5 years, we collaborated together on the development of Home Monitoring Point of Care Device. Rob is an excellent project partner, his expertise in dry chemistry optimization and microfluidic design is second to none and he has a very practical and forward thinking approach in project management. In addition, Rob has a helpful and approachable personality. I would strongly recommend Rob for any new assay development project.”
DeCromo Consulting
“The experience in the team at IVDS is unparalleled and they have delivered consistent results across multiple R&D disciplines. I have been personally very impressed by professional approach in meeting critical deadlines on time while maintaining the flexibility to adapt to change.”
Wen Wu PhD, President of Integrated Biomedical Technologies
“I have worked with Rob on and off for the last 30 years, he is one of the most creative scientists that I have ever met.”
Previous
Next
NEWS & EVENTS
Dr. Christiani presented IVDS at the 2021 Global PKU Patient Conference
IVDS presents at BioNJ's Tenth Annual Biopartnering Conference, scheduled virtually for October 6 & 7.
IVDS presentation in Virtual PKU Home Phe Monitor Webinar
IVDS presented "PKUNow" at The National PKU Alliance as simple to use point of care device with accurate and precise detection in the range of 1-25 mg/dL Phe in whole blood. "PKUNow" technology eliminates Tyrosine interference on Phenylalanine dehydrogenase.
IVDS received an Award from NJ small business success in 2018
NJSBDC has been instrumental in reviewing and editing IVDS grant applications and providing the insight for our commercialization. In addition, it's consultants are providing guidance as IVDS transitions from a development group in to a successful business that manufactures point of care devices.